Ameloblastic fibro-odontoma

Ameloblastic fibro-odontoma (AFO) is a rare, benign, mixed odontogenic tumor composed of proliferating odontogenic epithelium and cell-rich ectomesenchyme resembling dental papilla, together with dental hard tissues (enamel and dentin).[1][2] It occupies a conceptual position between ameloblastic fibroma and complex odontoma, and its precise biologic nature—true neoplasm versus hamartomatous developing odontoma—remains actively debated.[3][4] AFO occurs predominantly in children and adolescents, with a strong predilection for the posterior jaws.[5][6] The signature imaging pattern is a well-defined radiolucent area containing variable radiopaque foci, commonly associated with an unerupted tooth.[1][5] Behavior is typically indolent, and conservative surgical enucleation with curettage is the standard treatment, though rare cases exhibit locally aggressive growth.[3][5]

In the 2005 WHO Classification of Head and Neck Tumours, AFO was listed as a distinct mixed epithelial-mesenchymal odontogenic tumor alongside ameloblastic fibroma and ameloblastic fibrodentinoma.[3] The 2017 (4th edition) WHO classification removed AFO and ameloblastic fibrodentinoma as separate entities, reclassifying them as probable developing odontomas.[7] The 2022 WHO classification maintained this position but acknowledged that the issue requires further clarification, given that a substantial proportion of AFOs harbor BRAF p.V600E mutations—a molecular feature shared with ameloblastic fibroma but absent in odontomas.[8][9]

The term "ameloblastic fibro-odontoma" therefore remains in widespread clinical and pathological use despite its removal from the formal WHO tumor list. Older synonyms occasionally encountered include "soft and calcified odontoma" and "ameloblastic odontoma," though the latter term has also been applied to the distinct entity odontoameloblastoma and should be avoided to prevent confusion.[3][10]

• Age: AFO predominantly affects children and adolescents. In a systematic review of 215 central AFOs, the mean patient age was in the first to second decade of life. A molecular-focused series reported a mean age of 15.7 years for AFO and ameloblastic fibrodentinoma combined.[6][9]
• Sex: A slight male predominance has been reported across pooled data.[1][6]
• Frequency: AFO is rare. When odontomas are excluded from odontogenic tumor tallies, AFO accounted for approximately 7.3% of remaining odontogenic tumors in one large North American biopsy service.[11]
• Site: The posterior mandible is the most common location, followed by the posterior maxilla. The vast majority of AFOs are central (intraosseous); peripheral (extraosseous) AFO is exceedingly rare, with only isolated cases documented.[1][6][12]

AFO most commonly presents as a painless, slowly enlarging swelling in the posterior jaw of a child or adolescent.[1][13][14] The overlying mucosa is typically normal in color and texture.[13][14]

Presenting features

• Failure of tooth eruption is a frequent initial finding, often prompting the radiographic examination that reveals the lesion.[15][16]
• Buccal and occasionally lingual cortical expansion may be palpable, particularly in larger lesions.[14][17]
• The lesion is generally firm and non-tender on palpation.

Tempo and complications

• Growth is characteristically slow and indolent. Displacement of adjacent teeth is common; root resorption of neighboring teeth occurs but is not universal.[3][5][6][18]
• Rare cases demonstrate locally aggressive behavior with extensive bone destruction, cortical perforation, and multilocular expansion, occasionally requiring resection rather than conservative surgery.[3][5]
• Peripheral AFO presents as a gingival soft-tissue mass, typically in young children, and may mimic other gingival growths.[12]

The hallmark imaging appearance of AFO is a well-defined radiolucent area containing variable amounts of radiopaque material, typically associated with one or more unerupted or displaced teeth.[1][2][5]

Periphery and shape

• The lesion is characteristically well-circumscribed with a corticated or well-defined sclerotic border.[1][14][19]
• Most AFOs are unilocular; multilocular architecture is uncommon and, when present, may signal more aggressive behavior.[5][17]

Internal architecture

• The radiolucent component represents the soft-tissue portion of the tumor (odontogenic epithelium within cell-rich ectomesenchyme) and is a distinguishing feature from a mature odontoma, in which the soft-tissue component is minimal.[3][20]
• Radiopaque foci within the radiolucency vary widely in size, shape, and density, ranging from small scattered calcified flecks to larger, irregularly shaped masses with density approaching that of dental hard tissues (enamel and dentin).[1][2][14]
• The radiopaque material is arranged haphazardly without the organized tooth-like morphology seen in compound odontomas.[21]
• In some cases, lobular radiopaque masses with surrounding radiolucent rims may be observed.[15]

Location and distribution

• The posterior mandible (premolar–molar–ramus region) is the most frequent site, followed by the posterior maxilla.[1][6]
• The lesion is centered within the alveolar bone and may extend into the ramus or, in maxillary cases, into the maxillary sinus.[15]

Relationship to teeth

• Association with an unerupted or impacted tooth is a near-constant finding; the lesion typically occupies the expected position of the missing tooth or lies coronal to it.[15][17][19]
• Displacement of adjacent erupted and developing teeth is common.[6][14]
• Root resorption of neighboring teeth occurs at a rate comparable to that seen in ameloblastic fibrodentinoma.[6]

Effects on adjacent structures

• Cortical expansion, often involving both buccal and lingual plates, is typical of larger lesions.[6][14]
• Cortical perforation has been documented in a proportion of cases in systematic review data.[6]
• Large maxillary AFOs may opacify or displace the floor of the maxillary sinus.[15]
• The inferior alveolar canal may be displaced inferiorly by mandibular lesions.

Growth pattern and extent

• Most AFOs are small and unilocular with limited growth potential. However, occasional cases reach considerable size, occupying large segments of the jaw.[1][3][15][17]
• The extensive radiolucent (soft-tissue) component relative to the calcified portion is a key feature that distinguishes AFO from a mature complex odontoma, in which the radiolucent rim is thin and the bulk of the lesion is densely radiopaque.[3][20]
• Volumetric imaging is valuable for delineating the three-dimensional extent of the lesion, its relationship to vital structures (inferior alveolar nerve, maxillary sinus), the degree of cortical involvement, and surgical planning, particularly in large or aggressive cases.[17]

Aggressive variant

• Rarely, AFO presents as a large, multilocular, expansile lesion with cortical destruction and infiltrative margins, mimicking an ameloblastoma or other aggressive odontogenic tumor. This pattern warrants incisional biopsy before definitive surgery.[3][5]

CT (or CBCT with extended field of view) and, less commonly, MRI may be employed for large or aggressive AFOs to assess soft-tissue extent and the relationship to adjacent vital structures beyond what dental imaging alone can characterize.

• On CT, the soft-tissue component of AFO demonstrates low attenuation, while the calcified foci show high-density values consistent with enamel and dentin. CT is superior for delineating matrix mineralization patterns and cortical integrity.[17][22]
• MRI can help characterize the soft-tissue component, which typically shows intermediate signal on T1-weighted and high signal on T2-weighted sequences, reflecting the myxoid ectomesenchymal stroma. MRI is most useful when cortical perforation is suspected and soft-tissue extension into adjacent spaces (e.g., infratemporal fossa, orbit) needs evaluation.
• These modalities are not routinely required for small, well-defined AFOs but become important for surgical planning in extensive lesions or when the imaging appearance raises concern for a more aggressive process.[5][17]

The differential diagnosis centers on other mixed radiolucent-radiopaque odontogenic lesions of the posterior jaws in young patients. The prominent soft-tissue (radiolucent) component relative to the calcified material, association with an unerupted tooth, and patient age are the key discriminating features.

The highest-risk diagnostic pitfall is misidentifying a developing complex odontoma as AFO, or vice versa, because the two entities can be radiographically and histopathologically indistinguishable in early stages.[3] Incisional biopsy with careful histopathologic evaluation—and, when available, BRAF p.V600E mutation analysis of the mesenchymal component—can help resolve this distinction, as odontomas are consistently BRAF wild-type.[9][24]

The definitive diagnosis of AFO requires histopathologic confirmation demonstrating both a soft-tissue component resembling ameloblastic fibroma and dental hard tissue formation.[1][2]

Soft-tissue component

• Cell-rich ectomesenchyme resembling the dental papilla, composed of plump stellate and spindle-shaped cells in a myxoid to fibrous stroma.[13][21]
• Strands, cords, and islands of odontogenic epithelium with peripheral columnar or cuboidal cells and loosely arranged central cells; the epithelial pattern recapitulates the dental lamina and enamel organ but lacks the well-developed stellate reticulum seen in ameloblastoma.[3]

Hard-tissue component

• Tubular dentin and varying degrees of enamel matrix, arranged haphazardly without the organized morphology of normal teeth.[1][21]
• Cementum-like material may also be present.[1]
• The dental hard tissues are distributed within the soft-tissue stroma, distinguishing AFO from a mature odontoma in which hard tissue predominates and the stroma is mature fibrous connective tissue.[21]

Radiologic-pathologic correlation

The radiolucent zones on imaging correspond to the ectomesenchymal soft-tissue component, while the radiopaque foci correspond to the islands of enamel, dentin, and cementum.[1][14] A large radiolucent component relative to calcified material correlates with a prominent soft-tissue stroma and supports the diagnosis of AFO over mature odontoma.[3]

Molecular findings

• BRAF p.V600E mutation has been identified in the mesenchymal component of approximately 53% of AFOs, a rate similar to ameloblastic fibroma (~68%) and in stark contrast to odontomas, which are uniformly BRAF wild-type. A systematic review and meta-analysis confirmed an overall BRAF mutation prevalence of approximately 55.6% in the AFO/ameloblastic fibrodentinoma/developing odontoma group.[9][25]
• Copy number alterations (CNAs) in the mesenchymal component were detected in approximately 43% of AFOs, again absent in odontomas.[9]
• These molecular findings support the concept that at least a subset of AFOs are true neoplasms molecularly distinct from odontomas, rather than simple hamartomatous precursors.[9][24]
• BRAF V600E immunohistochemistry in ameloblastic fibroma shows staining in both stromal and epithelial components, reflecting the biphasic nature of the lesion, in contrast to ameloblastoma where staining is predominantly epithelial.[26]

Treatment

• Conservative surgical enucleation with curettage is the standard treatment for typical AFO and is curative in the vast majority of cases.[1][2][5][13]
• The well-encapsulated nature of most AFOs permits clean separation from surrounding bone.[18]
• In pediatric patients, conservative surgery is preferred to preserve developing teeth and jaw growth. Unerupted permanent teeth adjacent to the lesion may be preserved when feasible, and subsequent eruption has been documented.[13][14][15]

Aggressive or large lesions

• Rare cases with locally aggressive behavior (multilocular pattern, cortical destruction, infiltrative margins) may require more extensive resection, including segmental or marginal mandibulectomy with reconstruction.[5]
• Incisional biopsy is recommended before definitive surgery when imaging suggests aggressive features, to exclude ameloblastic fibrosarcoma or other malignancies.[3][5]

Recurrence

• Recurrence after conservative enucleation is low. In a molecular-focused series, no recurrences were observed among followed AFO cases. Multiple case reports and small series confirm recurrence-free follow-up periods of 2–12 years after enucleation.[9][13][17][27]
• Systematic review data show that the recurrence rate of AFO does not differ significantly from that of ameloblastic fibrodentinoma.[6]

Malignant transformation

• Ameloblastic fibro-odontosarcoma, the malignant counterpart, is exceedingly rare, with only approximately 12 cases reported. It may arise de novo or from a pre-existing AFO.[21][28][29]
• The sarcomatous transformation involves the mesenchymal component, which shows nuclear atypia, increased mitoses, and pleomorphism, while the epithelial component remains benign.[21][30]

Follow-up

• Long-term clinical and radiographic follow-up is recommended given the low but nonzero risk of recurrence and the rare possibility of malignant transformation. A minimum follow-up of 5 years is prudent, with periodic imaging to confirm osseous healing and absence of recurrence.[15][17]
• Oral rehabilitation, including dental implants, can be considered after confirmed disease-free status.[17]

Neoplasm-versus-hamartoma debate and classification implications

The biologic nature of AFO remains one of the most actively debated topics in odontogenic tumor classification. The 2017 and 2022 WHO classifications reclassified AFO as a developing odontoma rather than a distinct tumor entity.[7][8] However, several lines of evidence challenge this reclassification:

• A substantial proportion of AFOs harbor BRAF p.V600E mutations and copy number alterations in their mesenchymal component—molecular features shared with ameloblastic fibroma and ameloblastic fibrosarcoma but absent in all tested odontomas.[9][24][25]
• Some AFOs demonstrate locally aggressive behavior, including cortical destruction, multilocular expansion, and recurrence—features atypical of odontomas.[3][5][8]
• Systematic review data show that AFO and ameloblastic fibrodentinoma share similar clinical profiles (age, sex, site, size, recurrence rate) with ameloblastic fibroma rather than with odontomas, arguing against a simple maturation continuum.[6]

These findings suggest that AFO likely encompasses a heterogeneous group: some cases represent true developing odontomas (hamartomas), while others are genuine neoplasms molecularly related to ameloblastic fibroma.[4][8][9] The current WHO classification acknowledges that further clarification is needed.[8] From a practical standpoint, all excised AFOs should undergo thorough histopathologic evaluation, and BRAF mutation testing of the mesenchymal component may help stratify biologic risk when available.[9][24]

Pediatric considerations

Because AFO overwhelmingly affects children and adolescents during active jaw development, treatment planning must balance complete lesion removal against preservation of developing tooth germs and jaw growth potential.[13][14] Conservative enucleation with curettage achieves this balance in most cases, and eruption of preserved adjacent teeth has been documented after surgery.[15]